Garuda - Garba Rujukan Digital

p-Index From 2020 - 2025

1.168

P-Index

This Author published in this journals

All Journal HAYATI Journal of Biosciences Jurnal Farmasi Klinik Indonesia Jurnal Riset Veteriner Indonesia (Journal of The Indonesian Veterinary Research) Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) Majalah Farmasi dan Farmakologi (Trends in Pharmacy and Pharmaceutical Sciences) JSFK (Jurnal Sains Farmasi & Klinis) Jurnal Kedokteran Hewan

Muh. Akbar Bahar

Departemen Farmasi, Fakultas Farmasi, Universitas Hasanuddin, Makassar, Indonesia

Author-ID : 239850

Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Earth & Planetary Sciences Health Professions Immunology & microbiology Medicine & Pharmacology Public Health Veterinary

Published : 9 Documents Claim Missing Document

Claim Missing Document

Articles

EFEKTIVITAS SARILUMAB SEBAGAI KANDIDAT OBAT COVID19: SEBUAH KAJIAN SISTEMATIK sakiya syahrir sudirman; Dini Ayu Ariastiwi B; Marianti A.Manggau; Firzan Nainu; Muh.Akbar Bahar
Majalah Farmasi dan Farmakologi Vol. 25 No. 1 (2021): MFF
Publisher : Faculty of Pharmacy, Hasanuddin University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20956/mff.v25i1.12048

Penelitian ini bertujuan untuk mengetahui efektivitas dan keamanan penggunaan Sarilumab pada pasien COVID-19 berdasarkan kajian sistematik dari berbagai artikel penelitian yang telah dipublikasikan. Kajian sistematis ini disusun berdasarkan guideline PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). Studi yang diterbitkan setelah Desember 2019 dari database PubMed/MEDLINE dan EMBASE ditelusuri secara sistematis. Kombinasi kata kunci seperti "COVID-19”, "severe acute respiratory syndrome coronavirus 2”,dan "Sarilumab" digunakan untuk mencari artikel yang sesuai kriteria inklusi. Dari hasil penelusuran dan skrining artikel, diperoleh dua artikel yang memenuhi syarat kriteria inklusi yaitu satu artikel berupa laporan kasus dan satu artikel berupa seri kasus yang menunjukkan potensi sarilumab dalam pengobatan COVID-19. Pada artikel seri kasus, jumlah pasien yang terlibat sebanyak 8 orang yaitu 6 laki-laki dan 2 wanita dengan kondisi akhir tujuh pasien keluar lebih cepat dari perawatan di rumah sakit (dalam waktu 14 hari) karena telah memperlihatkan hasil negatif pada tes molekuler dan satu pasien yang berusia 83 tahun meninggal pada hari ke-13 di rumah sakit. Pada laporan kasus, pasiennya hanya 1 orang laki-laki dengan kondisi akhir pasien sembuh (hasil tes swab negatif) dan kondisi klinik yang baik. Sebagai kesimpulan, sarilumab berpotensi memberikan perbaikan klinis terhadap pasien COVID-19. Akan tetapi, karena kedua artikel tersebut memiliki kualitas bukti ilmiah yang lemah maka belum bisa dijadikan dasar rujukan penggunaan sarilumab untuk pasien COVID-19 di klinik.

Inflammation-mediated Phenoconversion: A Potential Threat to COVID-19 Pharmacotherapy Muh. Akbar Bahar; Bob Wilffert; Harapan Harapan; Firzan Nainu
HAYATI Journal of Biosciences Vol. 28 No. 1 (2021): January 2021
Publisher : Bogor Agricultural University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.4308/hjb.28.1.54

One of the important hallmarks of coronavirus disease 2019 (COVID-19) is the existence of severe inflammatory responses. Many reports indicated that inflammatory mediators might suppress the biological functions of some drug metabolizing enzymes and transporters, and therefore result in a transient mismatch between their genotype and phenotype expressions, a phenomenon which is called phenoconversion. The incidence might be clinically relevant to the COVID-19 patients with comorbidities. The patients are treated with multiple drugs that are prone to be altered pharmacokinetically by inflammation-mediated phenoconversion, leading to the modification of their effectiveness and safety. In this review, we discuss the regulation of inflammatory responses during COVID-19 infection and the evidence as well as potential mechanisms of inflammation-mediated phenoconversion. We also provide possible clinical implications of such phenoconversion events as a potential threat in the management of COVID-19 patients.

The Effect of Avocado to the Profile of Blood Urea Nitrogen (BUN) and Creatinine in Rats (Rattus norvegicus) Induced with Meloxicam Amelia Ramadhani Anshar; Muhammad Akbar Bahar; Dini Kurnia Ikliptikawati
Jurnal Riset Veteriner Indonesia (Journal of The Indonesian Veterinary Research) VOLUME 2 NO. 1, JANUARY 2018
Publisher : Hasanuddin University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20956/jrvi.v2i1.3802

Incidence of drug overdose during treatment of acute disease consequently leads to serious renal damage. As supporting treatment, administration of herbal medicine and food dietary are frequently developed. This research aimed to prove how the administration of avocado juice could lower the BUN and creatinine level in white rats induced with toxic doses of meloxicam. Meloxicam is a non-steroidal anti-inflamatory drug (NSAID), which is effectively used as an anti-inflamatory, analgesic, and antipyretic. Twenty four (24) male Wistar rats were assigned to 4 groups of six rats each (n=6). 1 ml of CMC 1% was administered to Control Group I, 30 mg/kgBB meloxicam and 1 ml of CMC 1% to Control Grup II, 30 mg/kgBB meloxicam and avocado juice 5 g/kgBB/day to Treatment Group I, and 30 mg/kgBB meloxicam and avocado juice 10 g/kgBB/day to Treatment Group II. The study was conducted over 8 days, then the level of Blood Urea Nitrogen and creatinine of the white rats were examined on the 1st and 8th day. The results were analyzed by Anova Two Way With Replication, then followed by T-test (α = 0,05) if there were difference. The Anova Two Way With Replication test showed that the mean of the four groups either the levels of Blood Urea Nitrogen or creatinine was significantly decreased (p<0,05). The decrease of BUN in the treatment group I was 27,17 27,17mg/dl and 17,83mg/dl while the decrease of creatinine level was 0,983mg/dl and 0,713mg/dl. The conclusion of this study was that avocado juice decreases level of Blood Urea Nitrogen and creatinine in white rats which exposed toxic doses of meloxicam.

Aktivitas Anti-inflamasi Ekstrak Etanol Daun Beluntas (Pluchea indica L.) pada Model Inflamasi Terinduksi CFA (Complete Freund's Adjuvant) : Anti-inflammatory Activity of Ethanol Extract of Beluntas Leaves(Pluchea indica L.) on Complete Freund's Adjuvant-induced Inflammatory Model Reza Setiawan Sudirman; Usmar Usmar; Abdul Rahim; Muh. Akbar Bahar
Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal) Vol. 3 No. 2 (2017): (October 2017)
Publisher : Universitas Tadulako

A research about anti-inflammatory effect of Beluntas leaves extract on CFA (Complete Freund’s Adjuvant) induced inflammatory model has been conducted. The objective of this research was to determine the effect of Beluntas leaves extract in alleviating CFA-induced paw edema in mice (Mus musculus). The number of mice used was 15 and was divided into 5 groups. Group I was treated with NaCMC. Group II, III, and IV were given suspension of Beluntas leaves extract 100 mg/Kg, 300 mg/Kg, and 500 mg/Kg BW, respectively. Group V was a positive control treated with suspension of diclofenac sodium 0.1 ml/10 g orally. The determination of anti-inflammatory potency was based on the average time needed to ameliorate the edema volume. The shortest time period of edema reduction was produced by diclofenac sodium (within 9.33 days), then followed by Beluntas leaves extract with the concentration of 300 mg/Kg (within 12 days), 500 mg/Kg (within 14.33 days), and 100 mg/Kg (within 17.67 days), consecutively. These results are significantly different compared to negative control group which did not reduce the edema volume during 18 days of observation. In conclusion, ethanol extract of Beluntas leaves has an effective anti-inflamatory effect.

STUDI PRAKLINIK EFEK SIMVASTATIN, ROSUVASTATIN, DAN FENOFIBRAT TERHADAP KADAR LAKTAT DEHIDROGENASE PADA TIKUS BETINA YANG DIINDUKSI KONTRASEPSI ORAL DAN DIET TINGGI LEMAK Yulia Yusrini Djabir; Yani Pratiwi; Muh Akbar Bahar
Majalah Farmasi dan Farmakologi Vol. 26 No. 1 (2022): MFF
Publisher : Faculty of Pharmacy, Hasanuddin University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20956/mff.v26i1.18125

Penggunaan pil kontrasepsi dapat menyebabkan peningkatan inflamasi yang terkait dengan resiko penyakit degeneratif pada wanita. Laktat dehidrogenase (LDH) merupakan biomarker peningkatan inflamasi dan kerusakan jaringan. Penelitian ini bertujuan mengetahui pengaruh pil kontrasepsi oral serta mengevaluasi efektivitas dari simvastatin, rosuvastatin, dan fenofibrat terhadap penurunan kadar LDH pada tikus betina (Rattus novergicus). Tikus (n=20) dibagi menjadi empat kelompok yaitu satu kelompok kontrol (pil kontrasepsi, pakan diet tinggi lemak dan NaCMC 0,5%), dan tiga kelompok perlakuan yang diberi pil kontrasepsi, pakan diet tinggi lemak dan obat uji: simvastatin (0,21 mg/kgBB), rosuvastatin (0,514 mg/kgBB) atau fenofibrat (8,246 mg/kgBB). Pemberian pil kontrasepsi dan pakan diet tinggi lemak dilakukan 30 hari.Pada hari ke-31, tikus diberi pengobatan sesuai kelompok perlakuan: kelompok kontrol diberikan plasebo (NaCMC), dan ketiga kelompok perlakuan, masing-masing diberikan obat uji simvastatin (0,21 mg/kgBB), rosuvastatin (0,51 mg/kgBB) serta fenofibrat (8,246 mg/kgBB) selama hari ke-30 hingga hari ke-60. Hasil menunjukkan bahwa pemberian pil kontrasepsi dan pakan diet tinggi lemak selama 30 hari menyebabkan peningkatan LDH pada semua kelompok tikus dan mencapai nilai signifikan pada kelompok simvastatin, rosuvastatin, dan fenofibrat (P<0,05). Setelah pemberian pengobatan selama 30 hari, kelompok simvastatin, rosuvastatin, maupun fenofibrat mengalami penurunan kadar LDH berturut-turut sebesar 25,8%, 27,1%, dan 27,9%. Penurunan kadar LDH dari ketiga jenis terapi tidak berbeda signifikan secara statistik. Dapat disimpulkan bahwa baik simvastatin, rosuvastatin maupun fenofibrat memiliki potensi menurunkan kadar LDH yang setara pada hewan model inflamasi sistemik yang diinduksi kontrasepsi oral dan diet tinggi lemak.

Effectiveness and Safety of Baricitinib as a Covid-19 Drug Candidate: A Systematic Review Yayuk S. Rahayu; Andi Anggriani; Habibie Habibie; Elly Wahyudin; Muhammad A. Bahar
Indonesian Journal of Clinical Pharmacy Vol 11, No 1 (2022)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15416/ijcp.2022.11.1.78

Baricitinib is an approved selective JAK1/JAK2 inhibitor that can potentially inhibit IL-6 as the primary driver of COVID-19-related cytokine storm syndrome. Therefore, this study aimed to assess the effectiveness and safety of baricitinib therapy in COVID-19 patients. It was reported following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search for eligible articles reporting the efficacy and safety of baricitinib on COVID-19 patients, published up to May 2021, was conducted using PubMed and Embase. The research protocol was registered at PROSPERO (CDR42021235282), and data were presented in a metasynthetic (descriptive) manner. Out of 878 identified articles, seven were eligible and consisted of three randomized clinical trials, one quasi-experimental study, two before-after (pre-post) studies, and one cross-sectional study. The articles suggested that baricitinib could improve the clinical conditions of COVID-19 patients indicated by negative PCR test results, improve breathing quality, and decrease: ICU requirements, length of hospital stay, as well as the risk of death. The trial studies showed that this inhibitor works better with a loading dose of 8 mg, continued with 4 mg daily. Baricitinib could also produce synergistic effects with standard therapy such as corticosteroid and remdesivir. Therefore, it is a promising candidate therapy for COVID-19 patients, but since the number and methodological quality of the studies are low, further and better research is needed to ascertain its potential use on COVID-19. Keywords: Baricitinib, COVID-19, JAK1/2 inhibitor Efektivitas dan Keamanan Baricitinib sebagai Kandidat Obat Covid-19: Tinjauan SistematisAbstrakBaricitinib adalah inhibitor selektif JAK1 JAK2 yang dapat menghambat IL-6 sebagai pemicu utama terjadinya sindrom badai sitokin terkait COVID-19. Tinjauan sistematis ini dilakukan untuk menilai efektivitas dan keamanan terapi baricitinib pada pasien COVID-19. Kami melaporkan penelitian ini dengan mengikuti pedoman Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA). Kami menggunakan mesin pencari PubMed dan Embase untuk mencari artikel yang melaporkan efektivitas dan keamanan baricitinib pada pasien COVID-19, yang diterbitkan hingga Mei 2021. Protokol penelitian ini telah terdaftar di PROSPERO (CDR42021235282). Data disajikan secara metasintetik (deskriptif). Di antara 878 artikel yang teridentifikasi, ada tujuh artikel yang memenuhi syarat yang terdiri dari tiga artikel uji klinis acak terkendali, satu studi kuasi-eksperimental, dua studi sebelum-sesudah (pra-pasca) dan satu studi cross-sectional. Semua artikel menyatakan bahwa baricitinib dapat memperbaiki kondisi klinis pasien COVID-19 yang ditunjukkan dengan hasil tes PCR negatif, meningkatkan kualitas pernapasan, dan menurunkan: kebutuhan ICU, lama rawat inap, dan resiko kematian. Baricitinib tidak menyebabkan efek samping yang serius. Hasil uji klinis menunjukkan bahwa baricitinib bekerja lebih baik dengan pemberian loading dose 8 mg lalu dilanjutkan dengan baricitinib 4 mg setiap hari dibandingkan tanpa loading dose baricitinib. Baricitinib juga menghasilkan efek sinergistik jika dikombinasikan dengan terapi standar seperti kortikosteroid dan remdesivir. Oleh karena itu, dapat disimpulkan bahwa baricitinib adalah kandidat terapi yang menjanjikan untuk pasien COVID-19. Namun, karena jumlah dan kualitas metodologi penelitiannya rendah, penelitian lebih lanjut dan lebih baik secara metodologi masih dibutuhkan untuk memastikan potensi penggunaan baricitinib pada COVID-19.Kata kunci: Baricitinib, COVID-19, inhibitor JAK1/2

Perbandingan Efektivitas Klinik Simvastatin dan Atorvastatin Terhadap Profil Lipid Darah: Studi Kasus di Rumah Sakit Universitas Hasanuddin Wenry Deston Latif; Muhammad Aswad; Muh. Akbar Bahar
Jurnal Sains Farmasi & Klinis Vol 9, No 1 (2022): J Sains Farm Klin 9(1), April 2022
Publisher : Fakultas Farmasi Universitas Andalas

Simvastatin dan atorvastatin merupakan obat golongan statin yang bekerja dengan menghambat enzim HMG CoA reduktase. Tujuan penelitian ini adalah mengevaluasi efektivitas klinik simvastatin dan atorvastatin dalam mempengaruhi profil lipid darah pasien dislipidemia di Rumah Sakit Universitas Hasanuddin Makassar. Penelitian ini merupakan studi cross sectional menggunakan data rekam medik pasien dislipidemia yang menggunakan simvastatin 10 mg dan atorvastatin 20 mg selama periode 2017-2020. Efektivitas obat golongan statin dinilai dari perubahan nilai LDL, TC, TG, dan HDL sebelum dan setelah penggunaan obat. Analisis regresi linear digunakan untuk menilai perbedaan efek simvastatin dan atorvastatin terhadap parameter lipid darah. Dibandingkan dengan simvastatin, perbedaan efek atorvastatin terhadap nilai LDL, TC, TG dan HDL, berturut-turut adalah 12,11±20,60 (95% Cl: -28,90-53,21), -11,70±11,30 (95% Cl: -14,84-38,24), -5,02±11,54 (95% Cl: -28,04-18,00) dan 0,42±4,04 (95% Cl: -7,65-8,48). Pasien yang menggunakan atorvastatin memiliki nilai akhir TC, HDL dan TG yang lebih baik dibandingkan simvastatin. Sementara pasien yang menggunakan simvastatin memiliki profil nilai akhir LDL yang lebih baik dibandingkan simvastatin. Hasil analisis statistik menunjukkan perbedaan yang tidak bermakna yang disebabkan karena terbatasnya jumlah pasien. Oleh karena itu, diperlukan studi dengan sampel yang lebih besar untuk melihat perbandingan efektivitas kedua jenis obat statin pada populasi pasien dislipidemia di Indonesia.

Clinical and Non-Clinical Predictors of Length of Stay in Indonesian hospitalized COPD (Chronic Obstructive Pulmonary Disease) Patients: Prediktor Klinik dan Non-Klinik Lama Rawat Inap Pasien PPOK (Penyakit Paru Obstruktif Kronis) di Rumah Sakit Matra Novalia Palipadang; Marianti A. Manggau; Muh. Akbar Bahar
Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal) Vol. 8 No. 2 (2022): (October 2022)
Publisher : Universitas Tadulako

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22487/j24428744.2022.v8.i2.16003

Background: COPD (chronic obstructive pulmonary disease) is a chronic disease characterized by persistent airflow limitation and is a major cause of morbidity and mortality. Objectives: This study aimed to analyze potential predictors of length of hospitalization (length of stay/ LOS) of COPD patients in the Anutapura Hospital, Central Sulawesi Province, Indonesia. Material and Methods: This study is an analytical descriptive using a cross-sectional design. The data were collected from medical records of COPD patients at Anutapura Hospital, Central Sulawesi Province, during 2018-2021. Information about demographic data (age, gender, weight), clinical data (comorbidities, single/combination antibiotics, route of antibiotic administration, type of antibiotics, oxygen therapy, history of hospital admission due to pneumonia, with/without exacerbations), and non-clinical data (type of insurance and treatment class) were extracted. Multivariate linear regression was used to identify the predictors of LOS. Results: A total of 210 COPD patients were identified. The results of univariate analysis showed that there were several potential predictors of LOS in COPD patients (p < 0.25), namely: age (B: 0.03, 95% CI: 0.01-0.05), treatment class (B: 1.16, 95% CI: 0.01-2.33), exacerbation (B: 0.55, 95% CI: -0.24-1.35), comorbidities (B: 0.68, 95% CI: 0.25-1.12), and single/combination antibiotics (B: 1.43, 95% CI: 0.33- 2.54). The results of the multivariate analysis indicated that the older (B: 0.03, 95% CI: 0.01-0.06, p = 0.02) COPD patients and the more comorbidities (B: 0.54, 95% CI: 0.07-1.00, p = 0.02) that they had, the longer the LOS that they experienced. Conclusions: In this study, age and patient comorbidities are independent predictors of LOS in COPD patients in the Anutapura Hospital, Central Sulawesi Province, Indonesia.

THE EFFECTS OF SIMVASTATIN, ROSUVASTATIN, AND FENOFIBRATE ON THE BODY WEIGHT AND LIPID PROFILES OF FEMALE RATS TREATED WITH ORAL CONTRACEPTIVES AND A HIGH-FAT DIET Putri, Dwi Anggara; Djabir, Yulia Yusrini; Bahar, Muhammad Akbar; Alam, Gemini; Rahman, Latifah; Aswad, Muhammad; Arsyad, Muhammad Aryadi
Jurnal Kedokteran Hewan Vol 16, No 3 (2022): September
Publisher : Universitas Syiah Kuala

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21157/j.ked.hewan.v16i3.22196

This study aimed to compare the effects of simvastatin, rosuvastatin, and fenofibrate therapies on the body weight and lipid profiles of the female rats receiving a combination of oral contraceptives (COC) and a high-fat diet (HFD). Twenty female Wistar rats (130-200 g) were divided equally into four groups. The rats received a standard diet for seven days, and their baseline lipid profiles were analyzed. All rats also received COC containing 15.1 g/kg levonorgestrel/3.1 g/kg estradiol with HFD for 60 days. Starting on day 31, the rats were given the respected treatment. The control group received the vehicle, whereas the others were treated with either simvastatin (2.1 mg/kg), rosuvastatin (0.5 mg/kg), or fenofibrate (8.2 mg/kg). Blood samples were taken on days 30 and 60. The results showed that the administration of COC+HFD and vehicle for 30 days increased the rats body weight and dyslipidemia, characterized by a significant decrease in Low-Density Lipoprotein (HDL) and an increase in total cholesterol (TC) and triglycerides (TG) levels (P0.05). Among the treatments, only fenofibrate was found to be able to prevent a significant weight gain in rats. Both fenofibrate and rosuvastatin inhibited a significant rise in TG and TC levels. Meanwhile, the simvastatin administration failed to do the same. Although statistically insignificant, all treatments increased rats HDL levels. Thus, it can be concluded fenofibrate was the most effective treatment among all in reducing weight gain and improving the lipid profile of dyslipidemic rats induced by oral contraceptives and a high-fat diet.

Co-Authors Abdul Rahim Amelia Ramadhani Anshar Andi Anggriani Arsyad, Muhammad Aryadi Bob Wilffert Dini Ayu Ariastiwi B Djabir, Yulia Yusrini Elly Wahyudin Firzan Nainu Gemini Alam Gemini Alam Habibie Habibie Harapan Harapan Ikliptikawati, Dini Kurnia Jamhari Jamhari Latifah Rahman Marianti A. Manggau Marianti A. Manggau Marianti A.Manggau Matra Novalia Palipadang Mufidah Mufidah Muhammad Aswad Muhammad Aswad Putri, Dwi Anggara sakiya syahrir sudirman Suparman Suparman Usmar Usmar Wenry Deston Latif Yani Pratiwi Yayuk S. Rahayu Yulia Yusrini Djabir

Title

Found 9 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 9 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 9 Documents
Search